Specialized Cancer Center Support Grant

总体摘要 加州大学圣地亚哥分校(UCSD)癌症中心由约翰·门德尔松于1977年创立，已 自1978年以来一直由NCI癌症中心支持赠款(CCSG)资助，并已举办 自2001年以来的全面状况。作为圣地亚哥唯一一家由NCI指定的综合性癌症中心 摩尔斯癌症中心(MCC)的使命是减少该地区癌症的影响，并 不仅是通过促进科学发现、研究培训和跨学科护理。我们的目标是创造， 翻译并提供癌症预防和护理方面的高影响力的发现和创新 了解集水区的需求，为下一代癌症研究人员做好准备。 因此，MCC的目标是：1)阐明癌症的生物学并催化跨学科团队 跨科学领域的科学；2)开发和测试创新的预防、诊断和治疗 方法；3)开展癌症预防和控制研究，以减少脆弱人群的癌症差异 人口；4)向代表性不足的少数群体提供尖端的多学科护理；5) 在受训人员的整个过程中提供培训和教育；以及6)制定和实施基于社区的 癌症教育和外展计划。为此，MCC汇集了来自5个UCSD的232名成员 学校(医学、工程、药学和药学、物理科学和生物 科学)和2个财团合作伙伴(一个现有的：圣地亚哥州立大学，一个新的：拉霍亚 研究所)。此外，MCC还整合了UCSD健康科学及其附属医院的资源 加州大学圣迭戈分校健康系统为癌症研究和临床护理提供了统一的方法。中冶履行使命 通过其5个研究计划(癌症生物学和信号、结构和功能)的活动 基因组学、实体肿瘤治疗、血液恶性肿瘤和癌症控制)，由 7共享资源(流式细胞术、显微镜、转基因小鼠、生物统计学、基因组学和 计算生物学、生物信息库和组织技术、生物行为学)，并提供基础设施 按社区外展、培训和教育、临床方案和数据管理以及方案 审查和监控。在中心主任兼助理副主任Scott Lippman博士的领导下- 负责癌症研究和护理的首席执行官MCC见证了巨大的增长。在项目期间，MCC 成员撰写了3931篇与癌症相关的研究文章，2017年获得1.282亿美元(DC)的支持 与癌症相关的年度同行评审资金(增加8%)；以及与癌症相关的年度总额 通过横向比较，研究基数为1.485亿美元，比上一项目期增长11%。 协作性同行评审赠款资金也从2013年的6,590万美元增加到6,990万美元 2017年(增长6%)。重要的是，MCC的33项科学发现通过41项转化为临床 研究人员发起的临床试验，比前一个项目期增加了14倍。

OVERALL ABSTRACT Founded in 1977 by John Mendelsohn, the Cancer Center at University of California San Diego (UCSD) has been continuously funded by the NCI Cancer Center Support Grant (CCSG) since 1978 and has held Comprehensive status since 2001. As the only NCI-designated Comprehensive Cancer Center in San Diego County, the mission of Moores Cancer Center (MCC) is to reduce the impact of cancer in the region and beyond by fostering scientific discovery, research training, and interdisciplinary care. Our goal is to create, translate, and deliver high-impact discoveries and innovations in cancer prevention and care through a deep understanding of the needs of the catchment area, and prepare the next generation of cancer researchers. Accordingly, MCC’s aims are to: 1) Elucidate the biology of cancer and catalyze trans-disciplinary team science across the science spectrum; 2) Develop and test innovative preventive, diagnostic, and therapeutic approaches; 3) Conduct cancer prevention and control research to reduce cancer disparities in vulnerable populations; 4) Provide underrepresented minorities with access to cutting edge multi-disciplinary care; 5) Provide training and education across the trainee continuum; and 6) Develop and implement community-based cancer education and outreach programs. To this end, MCC brings together 232 members from 5 UCSD Schools (Medicine, Engineering, Pharmacy and Pharmaceutical Sciences, Physical Sciences and Biological Sciences) and 2 consortium partners (one existing: San Diego State University, and one new: La Jolla Institute). Furthermore, MCC integrates the resources of UCSD Health Sciences and its affiliated hospitals in the UCSD Health System for a unified approach to cancer research and clinical care. MCC fulfills its mission through the activities of its 5 Research Programs (Cancer Biology and Signaling, Structural and Functional Genomics, Solid Tumor Therapeutics, Hematological Malignancies, and Cancer Control) that are supported by 7 Shared Resources (Flow Cytometry, Microscopy, Transgenic Mouse, Biostatistics, Genomics and Computational Biology, Biorepository and Tissue Technology, and Biobehavioral), and infrastructure provided by Community Outreach, Training and Education, Clinical Protocol and Data Management, and Protocol Review and Monitoring. Under the leadership of Dr. Scott Lippman, Center Director and Associate Vice- Chancellor for Cancer Research and Care, MCC has seen tremendous growth. During the project period, MCC members authored 3931 cancer-relevant research articles, and in 2017 were supported by $128.2 million (DC) in annual cancer-relevant peer-reviewed funding (8% increase); and the total annualized cancer-relevant research base was $148.5M, an increase of 11% from the previous project period by lateral comparison. Collaborative peer-reviewed grant funding also increased from annual total costs of $65.9M in 2013 to $69.9M in 2017 (6% increase). Importantly, 33 of MCC’s scientific discoveries were translated to the clinic through 41 investigator-initiated clinical trials, a 14-fold increase from the previous project period.